Prospective Postimplementation Study of Solana Group A Streptococcal Nucleic Acid Amplification Test vs Conventional Throat Culture

Sophie Arbefeville, Kari Nelson, Elizabeth Thonen-Kerr, Patricia Ferrieri

Research output: Contribution to journalArticle

3 Scopus citations


Objectives We evaluated the Solana Group A Streptococcus Assay (Quidel, San Diego, CA), a nucleic acid amplification test (NAAT), as a substitute for backup culture on throat specimens with a negative rapid group A Streptococcus (GAS) antigen assay. Methods During October 2016, all throat swabs from patients with a negative GAS antigen assay from local urgent care centers were processed by NAAT and conventional culture in real time. Results The overall agreement of the 2,090 tested throat swab specimens of the NAAT with the culture was 2,050 (98%) of 2,090. Sensitivity, specificity, positive predictive value, and negative predictive value were 91.4%, 98.5%, 78.0%, and 99.5%, respectively. Conclusions In summary, this postimplementation study supported high sensitivity and specificity of the GAS NAAT as a backup test for negative rapid GAS antigen tests.

Original languageEnglish (US)
Pages (from-to)333-337
Number of pages5
JournalAmerican journal of clinical pathology
Issue number4
StatePublished - Aug 30 2018



  • Group A Streptococcus
  • Pharyngitis
  • Rapid antigen detection test
  • Throat culture
  • ucleic acid amplification test

Cite this